Clinical Trial Update: Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma [Phase 2]

View source ↗

Summary

A Phase II, single-arm exploratory study evaluating tislelizumab in combination with anlotinib for advanced pulmonary pleomorphic carcinoma is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Pleomorphic Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Pulmonary Pleomorphic Carcinoma, Immunotherapy | Phase 2 | Status: RECRUITING